There is an upcoming biotech event co-produced annually by EBD Group, Inc. and Demy-Colton Life Science Advisors. Biotech Showcase 2013 investor and partnering conference is scheduled to be held from January 7 to 9, 2013 in San Francisco, CA at Parc 55 Wyndham San Francisco – Union Square.
It is considered an innovation showcase for life science investors. The three-day conference will have private and public equity investors, industry analysts, bankers, pharmaceutical and biotechnology industry executives as well as other industry professionals.
Now coming to biotech stocks, as we all know 2012 is near ending and many of you may want to know which companies have been performing relatively well in this industry. We found it interesting that 4 biotech companies have scored between 190% to over 400% in YTD performance and 1 has lost over 70% this year.
In 2012, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is on the top of the industry’s winner list with a year-to-date performance of 402.67%. The stock, as of last close, traded 522.52% up from its 52 week low and was -30.37% behind its 52 week high. Its latest closing price was 32.14% above the SMA200 while the distance from SMA 50 and SMA 20 was 7.20% and 4.40% respectively.
Another top performer, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has YTD performance up at 335.19%. Its price, as of the latest close, was up 347.62% compared with the 52 week low and was -28.13% below the 52 week high. The stock’s latest closing price was up +125.30% from the average-price of 200 days while it kept its distance from the SMA 50 at +50.56% and +8.31% compared with the SMA 20.
Galena Biopharma Inc (NASDAQ:GALE) has shown an uptrend of 242.55% this year with a monthly performance of -0.62% and 3-month performance down -14.36%. Its latest closing price was -4.94% down from an average-price of 200 days while it maintained a distance from the SMA 50 at -15.40% and -14.66% compared with the SMA 20. The stock was up 347.22% from the 52 week low and was -54.52% below the 52 week high.
The year-to-date performance of Affymax, Inc. (NASDAQ:AFFY) stands at 195.16% with an declined of -4.17% in the last three months and +207.73% in the previous twelve months. Its price, as of the latest close, was 224.63% up from the 52 week low and was -29.67% below the 52 week high. Its latest closing price was +13.98% up from an average-price of 200 days while it kept its distance from the SMA 50 at -18.21% and -16.96% compared with the SMA 20.
On the flip side, Oncothyreon Inc (USA) (NASDAQ:ONTY) so far this year moved down -71.11% and its monthly performance stands at -51.97%. The stock was down -34.63% from the 52 week low and was -76.27% below the 52 week high. Its latest closing price was -52.20% down from an average-price of 200 days while it kept its distance from the SMA 50 at -54.34% and -51.32% compared with the SMA 20.